The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Vamil Devan - Guggenheim Securities LLC - Analyst
: Hi, great. Thanks for taking my question. So I just have two, if I could. One, I understand what you're saying around the TL1A program and looking
to partner that. I'm wondering if you just -- if there's any more details you can share just in terms of what you saw in terms of the half-life or anything
else in the trial?
And then second on just the endometriosis side, it's interesting news there. So looking forward to hearing and learning more about that. But I'm
just curious right now if you can maybe just give some sense of the competitive landscape as you're thinking about sort of designing a Phase 2
trial in that indication or how that would look and how -- just generally how you design it and what's the right comparison to think about?
Question: Brendan Smith - Cowen and Company LLC - Analyst
: Hi, guys. Thanks for taking the question. Appreciate it. So maybe just a quick one first on actually just the profile for 101. And apologies if I missed
it here. But can you confirm if any of the potential partners you had been in touch with prior to now have already seen the data or if that's kind of
the plan over the next few weeks? I'm just wondering on initial feedback there. And then maybe quickly on 201.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 12, 2025 / 9:30PM, ABSI.OQ - Q3 2025 Absci Corp Earnings Call
I know you've talked a bit about kind of endometriosis versus alopecia. But just wondering if there's ever -- if there's any -- maybe even at a high
level, thoughts on market segmentation, just given 201's mechanism and any considerations on how you're thinking about enrollment for that?
Thanks.
Question: Sean Laaman - Morgan Stanley - Analyst
: Sean, just to gauge your confidence on the data that you do have of being able to partner 101 out. And what are you looking for in a partner?
Question: Sean Laaman - Morgan Stanley - Analyst
: Sure. And just on 201, just to sort of gauge your feeling on how easy the trial is going to be to recruit? I imagine it'd be a fairly facile process, but I
could be wrong. And then just maybe sort of the cost to getting it to sort of proof-of-concept status? And how long do you anticipate a patient
would need to be on drug to potentially reach the outcome that you're looking for?
Question: Sean Laaman - Morgan Stanley - Analyst
: Sorry, alopecia, sorry.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 12, 2025 / 9:30PM, ABSI.OQ - Q3 2025 Absci Corp Earnings Call
Question: Sean Laaman - Morgan Stanley - Analyst
: Got you, thank you.
Question: Ryan Cheng - JP Morgan - Analyst
: Hey, guys. Thanks for taking our questions this evening. As we think about the timing of the interim alopecia data and also the start of the Phase
2 endometriosis trial next year, will you want to wait for the interim data from alopecia before you start the endometriosis trial? Just curious if
there's any read-through between the two items.
Question: Ryan Cheng - JP Morgan - Analyst
: Got it. And maybe just one quick one about what we have seen so far from HOPE Medicine's 115, specifically in endometriosis. How much read-through
do you see from 115 to your 201 program so far? And how are you using the data that they have seen to your own advantage?
Question: Srikripa Devarakonda - Truist Securities - Analyst
: Hey guys, thank you so much for taking my question. For the in vivo program with 201, can you remind me if you expect to be able to target all
endometriosis patients or if there is any restriction or subgroups that you would expect to target? And I know it's really early. But when you think
about drugs that are standard of care that have been commercialized in endometriosis, what do you see as the hurdles in the space as you take
201 forward?
Question: Srikripa Devarakonda - Truist Securities - Analyst
: Okay. Thank you so much.
| 
